-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In 2021, under the background of strong demand in the downstream pharmaceutical industry and accelerated import substitution, orders from many pharmaceutical machine companies will increase significantly, and the pharmaceutical equipment industry as a whole will show a high prosperity
.
As of January 26, 2022, 8 pharmaceutical machine companies have disclosed their 2021 performance forecasts, of which 7 have achieved positive results and 1 has flat performance
.
Pharmaceutical Equipment (Photo source: Pharmaceutical Network) Among the 7 pharmaceutical machinery companies with good performance, those with a net profit of over 100 million yuan include Aoxing Life Technology, Tofflon, Canaan Technology, Chutian Technology
.
Among them, Tofflon expects to achieve a net profit of 765 million-904 million yuan attributable to shareholders of listed companies in 2021
.
Chutian Technology expects that the lower limit of net profit in 2021 is also more than 500 million yuan
.
In terms of growth rate, Aoxing Life Technology and Chutian Technology performed well, and it is expected that net profit will double
.
Among them, AUSTAR Life Technology expects to record a nearly 711% increase in net profit in 2021 compared to 2020
.
Chutian Technology expects that the net profit attributable to shareholders of listed companies in 2021 will increase by 149.
33%-199.
20% over the same period of the previous year
.
According to the relevant forecasts of the above-mentioned companies, the downstream pharmaceutical industry has strong demand.
Enterprises upgrade their single machines to overall solutions, improve their precise management concepts, actively deploy new products and new markets, and open high-end import substitution.
Factors such as support
.
For example, Chutian Technology stated that during the reporting period, the company focused on the development of biopharmaceutical equipment, has basically completed the layout of biopharmaceutical front-end equipment, and made great achievements in the high-end market and import substitution
.
From the perspective of the industry, the overall prosperity of the pharmaceutical equipment industry in 2021 will be relatively high, especially in the context of the rapid development of the biopharmaceutical industry, the high-end pharmaceutical equipment market will usher in great opportunities.
faster than rising
.
At the same time, the pace of import substitution of pharmaceutical equipment is also accelerating, bringing more digging space to the pharmaceutical machine companies that have laid out in advance.
.
Can the industry continue to thrive in 2022? Can the pharmaceutical equipment industry continue to thrive in 2022? This is a general concern of the market
.
From the current point of view of many industry insiders and industry researchers, the industry is still expected to maintain a high degree of prosperity this year
.
For example, Guohai Securities said that it is optimistic about the vigorous development prospects of the domestic pharmaceutical equipment industry.
It believes that domestic pharmaceutical equipment companies continue to invest in research and development to continuously upgrade their business models and gradually become the benchmark for China's high-end manufacturing segments.
With rapid growth, the industry has gradually faded its cyclical attributes and ushered in long-term growth
.
Guosheng Securities also analyzed and pointed out that domestic pharmaceutical equipment companies are accelerating import substitution under the epidemic, and it is expected to convert "one-time dividends" into "long-term capabilities" of enterprises
.
At the same time, the "Dongfeng" of biopharmaceuticals has arrived, and the "substitution + overseas" import of domestic pharmaceutical equipment is expected to drive continued high growth in performance
.
In general, the import substitution space of domestic pharmaceutical machines is generally favored by securities companies.
In recent years, domestic pharmaceutical machine companies, including Chutian Technology and Tofflon, have also paid more attention to international layout
.
For example, Canaan Technology predicted in September 2021 that the international market is an important part of the order expectations in the next 3 to 5 years.
From the perspective of the international market, with the continuous innovation of product technology, there will be more in the high-end market.
product export opportunities
.
At the same time, the quality of pharmaceutical equipment is related to the level of pharmaceutical production
.
Under the circumstance of stricter supervision of China's pharmaceutical industry and accelerated development towards high quality, the development of domestic pharmaceutical equipment from the low-end to the high-end market has also become a consensus in the industry
.
In September 2021, the "Guiding Opinions on Expanding Investment in Strategic Emerging Industries, Cultivating and Strengthening New Growth Points and Growth Pole" jointly issued by the four departments of China proposed to focus on supporting the production of high-end medical equipment and pharmaceutical equipment and other high-end equipment, implementing intelligent manufacturing, Pilot demonstration of intelligent construction
.
It is foreseeable that with the support of policies, the entire pharmaceutical equipment industry will accelerate its transformation towards high-end and release new vitality
.
According to the data, the scale of China's pharmaceutical equipment industry has approached 100 billion yuan, and it is expected to reach 200 billion yuan by 2025.
.
.
As of January 26, 2022, 8 pharmaceutical machine companies have disclosed their 2021 performance forecasts, of which 7 have achieved positive results and 1 has flat performance
.
Pharmaceutical Equipment (Photo source: Pharmaceutical Network) Among the 7 pharmaceutical machinery companies with good performance, those with a net profit of over 100 million yuan include Aoxing Life Technology, Tofflon, Canaan Technology, Chutian Technology
.
Among them, Tofflon expects to achieve a net profit of 765 million-904 million yuan attributable to shareholders of listed companies in 2021
.
Chutian Technology expects that the lower limit of net profit in 2021 is also more than 500 million yuan
.
In terms of growth rate, Aoxing Life Technology and Chutian Technology performed well, and it is expected that net profit will double
.
Among them, AUSTAR Life Technology expects to record a nearly 711% increase in net profit in 2021 compared to 2020
.
Chutian Technology expects that the net profit attributable to shareholders of listed companies in 2021 will increase by 149.
33%-199.
20% over the same period of the previous year
.
According to the relevant forecasts of the above-mentioned companies, the downstream pharmaceutical industry has strong demand.
Enterprises upgrade their single machines to overall solutions, improve their precise management concepts, actively deploy new products and new markets, and open high-end import substitution.
Factors such as support
.
For example, Chutian Technology stated that during the reporting period, the company focused on the development of biopharmaceutical equipment, has basically completed the layout of biopharmaceutical front-end equipment, and made great achievements in the high-end market and import substitution
.
From the perspective of the industry, the overall prosperity of the pharmaceutical equipment industry in 2021 will be relatively high, especially in the context of the rapid development of the biopharmaceutical industry, the high-end pharmaceutical equipment market will usher in great opportunities.
faster than rising
.
At the same time, the pace of import substitution of pharmaceutical equipment is also accelerating, bringing more digging space to the pharmaceutical machine companies that have laid out in advance.
.
Can the industry continue to thrive in 2022? Can the pharmaceutical equipment industry continue to thrive in 2022? This is a general concern of the market
.
From the current point of view of many industry insiders and industry researchers, the industry is still expected to maintain a high degree of prosperity this year
.
For example, Guohai Securities said that it is optimistic about the vigorous development prospects of the domestic pharmaceutical equipment industry.
It believes that domestic pharmaceutical equipment companies continue to invest in research and development to continuously upgrade their business models and gradually become the benchmark for China's high-end manufacturing segments.
With rapid growth, the industry has gradually faded its cyclical attributes and ushered in long-term growth
.
Guosheng Securities also analyzed and pointed out that domestic pharmaceutical equipment companies are accelerating import substitution under the epidemic, and it is expected to convert "one-time dividends" into "long-term capabilities" of enterprises
.
At the same time, the "Dongfeng" of biopharmaceuticals has arrived, and the "substitution + overseas" import of domestic pharmaceutical equipment is expected to drive continued high growth in performance
.
In general, the import substitution space of domestic pharmaceutical machines is generally favored by securities companies.
In recent years, domestic pharmaceutical machine companies, including Chutian Technology and Tofflon, have also paid more attention to international layout
.
For example, Canaan Technology predicted in September 2021 that the international market is an important part of the order expectations in the next 3 to 5 years.
From the perspective of the international market, with the continuous innovation of product technology, there will be more in the high-end market.
product export opportunities
.
At the same time, the quality of pharmaceutical equipment is related to the level of pharmaceutical production
.
Under the circumstance of stricter supervision of China's pharmaceutical industry and accelerated development towards high quality, the development of domestic pharmaceutical equipment from the low-end to the high-end market has also become a consensus in the industry
.
In September 2021, the "Guiding Opinions on Expanding Investment in Strategic Emerging Industries, Cultivating and Strengthening New Growth Points and Growth Pole" jointly issued by the four departments of China proposed to focus on supporting the production of high-end medical equipment and pharmaceutical equipment and other high-end equipment, implementing intelligent manufacturing, Pilot demonstration of intelligent construction
.
It is foreseeable that with the support of policies, the entire pharmaceutical equipment industry will accelerate its transformation towards high-end and release new vitality
.
According to the data, the scale of China's pharmaceutical equipment industry has approached 100 billion yuan, and it is expected to reach 200 billion yuan by 2025.
.
